Physician profile
Mark P Weir
NPI 1265866636
$7,652.84
in general payments reported to CMS, 2019-2025
27 companies · $1,287 in 2025
The $1,287 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.25 · 2020: $13.40 · 2021: $55.71 · 2022: $4,245 · 2023: $1,203 · 2024: $837 · 2025: $1,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,576 · Education: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,576.16 |
| Education | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,883.55 | 2022-2025 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $671.60 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $537.18 | 2022-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $167.58 | 2023-2025 | Dupixent |
| Vifor Pharma, INC. | $160.09 | 2022 | |
| Galvanize Therapeutics, INC | $141.44 | 2025 | Aliya System |
| Harmony Biosciences LLC | $139.21 | 2023-2025 | Wakix |
| Genzyme Corporation | $122.71 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $121.65 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Takeda Pharmaceuticals U.S.A., INC. | $116.07 | 2023-2025 | Aralast |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.49 | 2023-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Philips North America LLC | $88.75 | 2022-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Verona Pharma, INC. | $72.61 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $67.09 | 2025 | Tyvaso |
| Amgen INC. | $39.28 | 2023-2025 | Tezspire |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $33.66 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $26.24 | 2023-2024 | Winrevair |
| Ani Pharmaceuticals, INC. | $23.48 | 2025 | Purified Cortrophin Gel |
| Amneal Pharmaceuticals LLC | $22.33 | 2025 | Unithroid |
| Lilly USA, LLC | $20.52 | 2025 | Zepbound |
| Pfizer INC. | $18.42 | 2024 | |
| Genentech USA, INC. | $16.99 | 2025 | Xolair |
| Avadel Cns Pharmaceuticals, LLC | $16.15 | 2024 | Lumryz |
| Ambu INC. | $14.49 | 2021 | |
| Mylan Specialty L.P. | $13.61 | 2024 | Yupelri |
| Covidien LP | $13.40 | 2020 | |
| Electromed, INC. | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Weir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.